newsfilter
← Latest News
GlobeNewswire·

AEON Reports Expanded Structural Data Supporting Molecular Similarity of ABP-450 to BOTOX®

  • Complementary peptide-mapping methods increased coverage of the active botulinum neurotoxin primary sequence for ABP-450 from approximately 93% to 98%, with 100% amino acid identity across all analyzed regions
  • Preliminary analysis confirms the preservation of the critical C430-C454 disulfide bond connecting the light & heavy chains, representing approximately 99% of total species in both ABP-450 & BOTOX®
  • Expanded primary structure analysis was performed across six drug product samples, including both ABP-450 & BOTOX®, demonstrating identical sequences at the critical proteolytic activation junction
  • AEON Biopharma expects FDA feedback from a planned Biosimilar Biological Product Development Type 2b interaction in the second half of 2026 to inform the next phase of ABP-450 development
  • A previous BPD Type 2a meeting in January 2026 provided FDA support for the proposed analytical similarity strategy under the 351(k) biosimilar pathway